Tamoxifen, antidepressants, and CYP2D6: the conundrum continues.
David
D
Holzman
D000928:Antidepressive Agents / Q000494:pharmacology*; D018931:Antineoplastic Agents, Hormonal / Q000493:pharmacokinetics*; D047072:Aromatase Inhibitors / Q000494:pharmacology*; D001943:Breast Neoplasms / Q000188:drug therapy / Q000517:prevention & control*; D019389:Cytochrome P-450 CYP2D6 / Q000235:genetics; D065690:Cytochrome P-450 CYP2D6 Inhibitors; D005260:Female; D006801:Humans; D017698:Postmenopause; D017697:Premenopause; D012008:Recurrence; D020845:Selective Estrogen Receptor Modulators / Q000493:pharmacokinetics*; D017367:Selective Serotonin Reuptake Inhibitors / Q000494:pharmacology*; D013629:Tamoxifen / Q000031:analogs & derivatives / Q000493:pharmacokinetics* / Q000494:pharmacology
D000928:Antidepressive Agents; D018931:Antineoplastic Agents, Hormonal; D047072:Aromatase Inhibitors; D019389:Cytochrome P-450 CYP2D6; D065690:Cytochrome P-450 CYP2D6 Inhibitors; D020845:Selective Estrogen Receptor Modulators; D017367:Selective Serotonin Reuptake Inhibitors; D013629:Tamoxifen; C055492:4-hydroxy-N-desmethyltamoxifen